Cardiovascular Disease Risk Markers in HIV-Infected Patients Receiving Abacavir or Tenofovir

In patients randomly assigned to receive abacavir or tenofovir, there was no difference in flow-mediated vasodilation or in inflammatory or coagulation biomarkers.

In 2008, the observational DAD study suggested a link between recent abacavir use and increased risk for myocardial infarction (MI; NEJM JW AIDS Clin Care Apr 14 2008). Since that time, multiple studies have examined this association, with some finding a link and others — including a large meta-analysis conducted by the FDA — finding no connection (NEJM JW AIDS Clin Care Jun 27 2011). To shed light on this controversy, investigators (with support from abacavir's manufacturer) conducted a cross-sectional analysis of cardiovascular disease risk markers in HIV-infected adults who had been randomly assigned — through previous participation in a clinical trial — to receive either abacavir or tenofovir for initial therapy.

Forty-six patients recei…

Reviewing Author

Rajesh T. Gandhi, MD

Disclosures

Grant/Research SupportNIH

Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)

Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)

Rajesh T. Gandhi, MD

Disclosures

Grant/Research SupportNIH

Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)

Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)

Cardiovascular Disease Risk Markers in HIV-Infected Patients Receiving Abacavir or Tenofovir

Topics

Reviewing Author